About
At Terremoto, we are creating a seismic shift in the breadth of pursuable targets. Our ultimate goal? To deliver highly targeted, small molecule medicines with optimized clinical profiles and superior therapeutic benefit.
At Terremoto, we are creating a seismic shift in the breadth of pursuable targets. Our ultimate goal? To deliver highly targeted, small molecule medicines with optimized clinical profiles and superior therapeutic benefit.
The world has witnessed incredible advances in drug development over the last two decades, including new drugs for previously intractable targets. And yet, many patients still face too few treatment options, notably in devastating conditions like cancer.
At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.
We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.
With the deep knowledge of our founders, leadership and overall team, we have the ability to translate our ambitious vision into real treatments. Most importantly, our group has set the industry standard for rapidly delivering these medicines to patients – a record we intend to maintain with our platform approach.